

Sunday, March 1, 2026

🎧: Simultaneous interpretation is provided BS : Breakfast Seminar LS : Luncheon Seminar

🎧: Simultaneous interpretation is provided BS : Breakfast Seminar LS : Luncheon Seminar

		7:30		8:00		9:00		10:00		11:00		12:00		13:00		14:00		15:00		16:00		17:00		18:00		19:00		20:00		21:00	
Hall Building	Room 1							9:20~10:50 Sponsored Symposium 3 Latest future perspective of Multiple Myeloma Emiko Sakaida, Hiroshi Handa (Novartis Pharma K.K.) P.16				12:00~12:50 LS15 Novel strategy for the separation of GVHD and GVL (Novartis Pharma K.K.)		13:05~14:35 Presidential Symposium Advancing Hematopoietic Cell Transplantation Through Clinical Research Takahiro Fukuda Takanori Teshima P.16				15:15~16:00 Plenary Session Masayuki Hino Shingo Yano P.17		Closing Remarks											
	4F Hall C																														
	Room 2	7:45~8:35 BS1 Long-Term Follow-Up Care after Hematopoietic Cell Transplantation: Supporting Life Beyond Treatment (Meiji Seika Pharma Co., Ltd.)		8:45~9:45 Nursing Symposium Finding Meaning and Growth in Hematopoietic Cell Transplantation Nursing Ikue Okuda Junko Kojima P.18		9:50~10:50 Multidisciplinary Team Care 3 Integrating Nutrition, Exercise, and Social Resources Yuichiro Nawa Hisayo Doi P.18						12:00~12:50 LS16 Motivational Interviewing for Hematologic Cancer Patients: Benefits and Outcomes (CHUGAI PHARMACEUTICAL CO.LTD.)		13:05~14:05 Nursing Oral Session 2 Clinical Practice and Care for HSCT Patients Mikiko Nakamura Yumie Morikage P.83		14:20~15:50 Symposium 8 CBT Update Naoyuki Uchida Satoshi Takahashi P.19															
	7F Hall B7 (1)																														
	Room 3	7:45~8:35 BS2 Fungal infections after allogeneic hematopoietic cell transplantation: from prophylaxis to treatment (MSD K.K.)		8:45~10:15 Sponsored Symposium 4 Infectious disease management after allogeneic hematopoietic stem cell transplantation Yoshinobu Kanda, Keiji Okinaka (Takeda Pharmaceutical Company Limited) P.19								12:00~12:50 LS17 Optimizing CAR T Cell Therapy: Insights from Real-World Data and Clinical Practice (Gilead Sciences K.K.)		13:10~14:10 Nursing Group Meeting				14:35~15:50 Symposium 9 Vaccination in Hematopoietic Stem Cell Transplant Recipients Keiji Okinaka Toshihiro Matsui P.20													
	7F Hall B7 (2)																														
	Room 4	7:45~8:35 BS3 Break the Wall, Fast Response, New Morning ~Innovative Treatment Strategies for Multiple Myeloma with Bispecific Antibodies (Pfizer Japan Inc.)		8:45~10:15 Symposium10 Advances in the Evaluation and Management of Steroid-Resistant Intestinal GVHD Ken-ichi Matsuoka Hideki Nakasone P.20								12:00~12:50 LS18 New Treatment Frontiers in Relapsed/Refractory DLBCL and FL: The Expanding Role of Immunotherapy (Genmab K.K. / Abbvie GK)		13:30~14:30 HCTC Recertification Seminar				14:45~15:45 Nursing Educational Lecture 2 Transplant Nursing in Action: Advancing Excellence Through Evidence-Based Practice P.21		Speaker: Mizuki Watanabe Chair: Fuyuko Tokunaga											
	5F Hall B5																														
	Room 5	7:45~8:35 BS4 Advancing MPN Care on the Path to Transplant: The Role of Ruxotinib in Real-World Practice (Novartis Pharma K.K.)		8:45~9:15 Educational Lecture 7 Speaker: Yoshihiro Inamoto Chair: Chikako Ohwada P.21		9:20~9:50 Educational Lecture 8 Speaker: Ayumu Ito Chair: Naoyuki Uchida P.21		9:55~10:25 Educational Lecture 9 Speaker: Takanori Teshima Chair: Takahiro Fukuda P.21		10:30~11:00 Educational Lecture 10 Speaker: Takashi Tanaka Chair: Tsuneaki Hirakawa P.21		12:00~12:50 LS19 A New Immunotherapy-Driven Therapeutic Framework for Relapsed/Refractory Follicular Lymphoma (Incyte Biosciences Japan G.K.)						14:40~15:10 Educational Lecture 11 Speaker: Yoshihiro Inamoto Chair: Motohiro Kato P.22		15:15~15:45 Educational Lecture 12 Speaker: Yasuhiro Nannya Chair: Hideki Goto P.22											
	7F Hall D7																														
	Room 6	7:45~8:35 BS5 The immunological mechanisms and clinical significance of Ropogeninterferon alfa-2b (PharmEssentia Japan KK)		8:45~9:45 The allied organizations forum for promoting hematopoietic stem cell transplantation P.22		10:00~11:00 Symposium11 Efforts to Shorten Bone Marrow Bank Coordination Shinichiro Okamoto Masayuki Hino P.23						12:00~12:50 LS20 Cytomegalovirus Infection after Hematopoietic Cell Transplantation ~ How to Prevent It and How to Overcome It ~ (MSD K.K.)		13:30~15:45 Public Forum																	
	5F Hall D5																														
	Room 7	7:45~8:35 BS6 Clinical Significance of CAR-T Cell Therapy in Multiple Myeloma (Bristol Myers Squibb K.K.)		8:45~9:45 Oral Session 23 Transplant Outcomes: ALL Takayoshi Tachibana P.55		9:50~10:50 Oral Session 24 CAR-T: Complications 2 Kyoko Yoshihara P.56						12:00~12:50 LS21 (Therakos JapanK.K.)		13:30~15:45 Special Public Lecture P.24																	
	1F Hall D1																														
Room 8	7:45~8:35 BS7 Significance of MFC-Based MRD Assessment in AML Management and Its Clinical Application to Treatment (Astellas Pharma Inc.)		8:45~9:45 Oral Session 25 Health Economics Chihiro Yamamoto P.57		9:50~10:50 Oral Session 26 Late Complications 2 Chikako Ohwada P.58						12:00~12:50 LS22 Advances in B-Cell-Targeted Therapies and Infectious Risk Management ~The Role of Immunoglobulin Replacement Therapy (CSL Behring K.K.)						14:40~15:52 Oral Session 27 Transplant Outcomes: AML/MDS Mineo KurokawaP.59														
4F G402																															
Room 9	7:45~8:35 BS8 A New Treatment Option Targeting BCMA ~ Belantamab Mafodotin in Second-Line Treatment ~ (GlaxoSmithKline K.K.)		8:45~9:45 Oral Session 28 GVHD Prophylaxis 2 Junya Kanda P.60		9:50~10:50 Oral Session 29 CAR-T: Lymphoma 1 Seitaro Terakura P.61						12:00~12:50 LS23 Team-Based Care for Patients with Relapsed/Refractory Multiple Myeloma (Pfizer Japan Inc.)						14:40~15:52 Oral Session 30 CAR-T: Lymphoma 2 Noriko Doki P.62														
4F G409																															
Room 10	7:45~8:35 BS9 Management Strategies for CMV and Secondary Immunodeficiency After Transplantation (Takeda Pharmaceutical Company Limited)		8:45~9:45 Oral Session 31 Rehabilitation Kazushi Nakamura P.64		9:50~10:50 Oral Session 32 Transplant Outcomes: Pediatric Masahiro Hirayama P.65						12:00~12:50 LS24 Considering Hematopoietic Cell Transplantation for Inborn Errors of Metabolism (Clinigen K.K.)						14:40~15:52 Oral Session 33 Transplant Immunology: Basic Science Daigo Hashimoto P.66														
5F G502																															
Room 11	7:45~8:35 BS10 Immune Thrombocytopenia (ITP) Treatment Drug 'Vyvgart Intravenous Infusion' (argenx Japan K.K.)		8:45~9:45 Oral Session 34 English: CAR-T Shinichi Makita P.67		9:50~10:26 Oral Session 35 English: Conditioning Chiki Nakaseko P.69						12:00~12:50 LS25 The benefits and reconsideration of treatment strategies for ixazomib in the new era of multiple myeloma therapy (Takeda Pharmaceutical Company Limited)						14:45~15:45 Oral Session 36 Stem Cell Source 1 Hideki Nakasone P.70														
5F G510																															
Room 12	7:45~8:35 BS11 Euroflow approach to MRD and Immune monitoring post CAR-T cell therapy in B-NHL /ALL and myeloma (Nippon Becton Dickinson Company Ltd.)		8:45~9:45 Oral Session 37 Conditioning Shinsuke Takagi P.72		9:50~10:50 Oral Session 38 Stem Cell Source 2 Kaito Harada P.73						12:00~12:50 LS26 Optimizing Transplantation Strategies and the Role of Blinatumomab in ALL (Amgen K.K. / Astellas Pharma Inc.)						14:40~15:52 Oral Session 39 Early Complications 2: VOD/TMA Kimikazu Yakushijin P.75														
6F G602																															
Room 13																															
6F G610																															
Room 14	7:45~8:35 BS12 New developments in WM/LPL treatment (BeOne Medicines Japan)		8:45~9:45 Oral Session 43 HCTC Kanayo Takahashi P.79		9:50~10:50 Oral Session 44 Recurrence: Minimal Residual Disease Yuho Najima P.80						12:00~12:50 LS28 High-Risk Acute Myeloid Leukemia (Nippon Shinyaku Co., Ltd.)		13:10~14:10 Symposium 12 The Role of Exercise and Nutrition in Post-Transplant Survivorship Satoshi Iyama Daisuke Kiguchi P.25		14:10~14:40 Exchange Meeting Daisuke Kiguchi		14:45~15:45 Oral Session 45 CAR-T: Myeloma Nobuhiro Tsukada P.81														
7F G701																															
Hall Building	Poster			8:30~11:00		Poster viewing				11:00~11:45 Poster Presentation		11:45~14:30 Poster viewing		14:30~15:30 Poster removal																	
	B2F Hall E1									P.108																					
	Exhibition			8:30~15:30								Exhibition																			
	B2F Hall E1																														
	5F Hall B5 Fover																														

Poster Presentation

P17

Stem Cell, Apheresis

Wataru Takeda

P18

Stem Cell Source

Junichi Sugita

P19

Chronic GVHD 2

Masako Toyosaki

P20

CAR-T: Myeloma, ALL

Satoshi Yoshihara

P21

CAR-T: Complications

Fumiaki Jinnouchi

P22

Transplant Outcomes: Pediatric

Katsutsugu Umeda

P23

Transplant Outcomes: AML/MDS

Ken Ishiyama

P24

Transplant Outcomes: MDS/MPD

Toshiro Kurokawa

P25

Transplant Outcomes: B-cell Lymphoma

Tomoyasu Jo

P26

Early Complications: Engraftment

Akio Kohno

P27

Early Complications: Others

Shinichi Kako

P28

Infection: Viral

Takehiko Mori

P29

LTFU/Late Complications 2

Saiko Kurosawa

P30

Rehabilitation 2

Takuro Sakurai

Nursing Poster Presentation

看P6

Education for Nurses

Kazue Mori

看P7

Follow-up Care for Post HSCT Patients

Nao Kawashima

看P8

CAR-T Cell Therapy Nursing

Yuka Okamura

看P9

Infection, Safety, and Devices

Mika Terada

看P10

Nurses' Experiences and Challenges

Takako Ohba